Bregal Sagemount and Ardian Invest in Ennov to Accelerate Growth

Bregal Sagemount, a leading growth-focused private equity firm, has announced a strategic growth investment in Ennov, a global provider of regulatory, quality, and clinical software solutions for life sciences and healthcare companies. The investment, made in partnership with Ardian, a global private investment firm, aims to accelerate Ennov’s expansion, particularly in AI innovation and global go-to-market efforts. The deal was announced on May 12, 2026.

Ennov, headquartered in Paris, offers a unified compliance platform that integrates regulatory, quality, commercial, clinical, and pharmacovigilance processes. Its software replaces fragmented legacy systems, enabling approximately 650 customers and over 500,000 users across 30 countries to manage complex regulatory requirements efficiently under authorities such as the FDA and EMA.

While the financial terms of the deal remain undisclosed, the transaction is expected to close by the end of June 2026, pending regulatory approvals and customary closing conditions. Legal advisors included Goodwin Procter LLP for Bregal Sagemount, Proskauer Rose LLP for Ardian, and Veil Jourde for Ennov.

Bregal Sagemount, with offices in New York and Palo Alto, has raised $11 billion in cumulative capital and specializes in providing flexible capital and strategic support to high-growth companies across sectors including software, financial technology, and healthcare IT. Ardian operates globally with 22 offices and manages $200 billion in assets, focusing on private equity, real assets, and credit.

Gene Yoon, Managing Partner at Bregal Sagemount, highlighted the increasing complexity and cost of regulatory and quality workflows in life sciences. He emphasized Ennov’s mission-critical software and its potential to optimize customer processes, particularly with the integration of new AI capabilities. Olivier Pâris, Founder and CEO of Ennov, expressed enthusiasm about partnering with investors who understand the intricacies of life sciences compliance and the opportunity to build AI-enabled solutions.

The investment supports Ennov’s strategic objectives to expand its product suite, enhance compliance and data management capabilities, and grow its presence in North American and European markets. The partnership is expected to generate synergies through cross-selling opportunities within the investors’ portfolios, operational efficiencies, and accelerated product development.

Industry trends show increasing consolidation in regulatory technology, with competitors likely to respond by enhancing innovation and customer service. Key challenges for Ennov include aligning strategic priorities between the two private equity owners, integrating technology platforms, and retaining key talent during the transition.

With this investment, representatives from both Bregal Sagemount and Ardian will join Ennov’s board, signaling a collaborative approach to governance and growth. The deal positions Ennov to strengthen its market leadership and deliver enhanced value to life sciences organizations navigating complex regulatory environments.

Looking ahead, Ennov plans to leverage combined expertise and resources to accelerate innovation and expand its global footprint, supporting customers in bringing products to market faster while maintaining compliance.